News

ascopubs.org3d
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small ...
This phase II study demonstrated the efficacy of osimertinib 80 mg daily in patients with EGFR mutant NSCLC with leptomeningeal disease. The study designed included BICR using the RANO-LM assessment ...
ascopubs.org5d
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.
Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma. This is an ASCO Meeting ...